SCHEMBL529952

SCHEMBL529952

CC(C)[C@@H]1CC[C@@H](C)C[C@H]1C(=O)NCCc1ccccn1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 3/20 0.52
ALOX5AP P20292 1/20 0.48
HSD11B1 P28845 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
TAS1R3 Q7RTX0 2/20 0.46
TAS1R1 Q7RTX1 2/20 0.46
ALDH1A1 P00352 3/20 0.46
HTT P42858 1/20 0.44
ATM Q13315 1/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
ADAM17 P78536 1/20 0.42
CYP3A4 P08684 3/20 0.42
LMNA P02545 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15342927 1.00 TRPM8 (0.52) TRPM8ALOX5APHSD11B1SMN1; SMN2TAS1R3
SCHEMBL29533375 1.00 TRPM8 (0.52) TRPM8ALOX5APHSD11B1SMN1; SMN2TAS1R3
SCHEMBL31486820 1.00 TRPM8 (0.52) TRPM8ALOX5APHSD11B1SMN1; SMN2TAS1R3
SCHEMBL2628659 1.00 TRPM8 (0.52) TRPM8ALOX5APHSD11B1SMN1; SMN2TAS1R3
SCHEMBL31658232 1.00 TRPM8 (0.52) TRPM8ALOX5APHSD11B1SMN1; SMN2TAS1R3
SCHEMBL23062653 1.00 TRPM8 (0.52) TRPM8ALOX5APHSD11B1SMN1; SMN2TAS1R3
SCHEMBL4132345 1.00 TRPM8 (0.52) TRPM8ALOX5APHSD11B1SMN1; SMN2TAS1R3
SCHEMBL1159800 1.00 TRPM8 (0.52) TRPM8ALOX5APHSD11B1SMN1; SMN2TAS1R3
SCHEMBL29007016 1.00 TRPM8 (0.52) TRPM8ALOX5APHSD11B1SMN1; SMN2TAS1R3
SCHEMBL10044144 1.00 TRPM8 (0.52) TRPM8ALOX5APHSD11B1SMN1; SMN2TAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122028893-A Composition and method for producing the same 奇华顿股份有限公司 2026-05-12 CN claimed
CN-117956976-A Nonaqueous oral composition 狮王株式会社 2024-04-30 CN claimed
US-20240058259-A1 COMPOSITIONS COMPRISING ESSENTIAL OILS FIRMENICH SA (CH) 2024-02-22 US claimed
EP-4192422-A1 COOLING SENSATION COMPOSITIONS Givaudan SA (CH) 2023-06-14 EP claimed
CN-116018128-A Cooling composition 奇华顿股份有限公司 2023-04-25 CN claimed
EP-2906196-B1 COSMETIC OR DERMATOLOGICAL PREPARATION FOR PROPHYLAXIS AND/OR TREATMENT OF ATOPIC DERMATITIS BEIERSDORF AG (DE) 2022-08-31 EP claimed
EP-3996505-A1 SYNERGISTIC FORMULATIONS FOR CONTROL AND REPELLENCY OF BITING ARTHROPODS Bedoukian Research, Inc. (US) 2022-05-18 EP claimed
EP-3996506-A1 FORMULATIONS FOR CONTROL AND REPELLENCY OF BITING ARTHROPODS Bedoukian Research, Inc. (US) 2022-05-18 EP claimed
WO-2022028726-A1 COOLING SENSATION COMPOSITIONS GIVAUDAN SA (CH) 2022-02-10 WO claimed
US-11059783-B2 Pyridinyl cyclohexanecarboxamide cooling compounds GIVAUDAN S.A. (CH) 2021-07-13 US claimed
EP-2168957-B1 Alkyl-substituted tetrahydropyranes as aromatic materials SYMRISE AG (DE) 2012-02-15 EP claimed
WO-2012013515-A2 SKIN PATCH HAVING OPTIMIZED ACTIVE SUBSTANCE RELEASE BEIERSDORF AG (DE) 2012-02-02 WO claimed
US-20110091531-A1 Cooling Composition GIV AUDAN SA (CH) 2011-04-21 US claimed
US-20100226864-A1 ALKYL-SUBSTITUTED TETRAHYDROPYRANS AS FLAVORING SUBSTANCES SYMRISE GMBH & CO. KG (DE) 2010-09-09 US claimed
EP-2168957-A2 Alkyl-substituted tetrahydropyranes as aromatic materials Symrise GmbH & Co. KG (DE) 2010-03-31 EP claimed
US-20100035938-A1 Cooling Compounds GIVAUDAN SA (CH) 2010-02-11 US claimed
US-20090311206-A1 COOLING COSMETIC OR DERMATOLOGICAL PREPARATIONS COMPRISING (1R,2S,5R)-2-ISOPROPYL-5-METHYL-N-(2-(PYRIDIN-2-YL)ETHYL)-CYCLOHEXANE CARBOXAMIDE AND/OR (1R,2S,5R)-N-(4-CYANOMETHYL-PHENYL)-2-ISOPROPYL-5-METHYLCYCLOHEXANE CARBOXAMIDE FOR REDUCING SKIN REDDENING BEIERSDORF AG (DE) 2009-12-17 US claimed
US-20090306152-A1 COOLING COSMETIC OR DERMATOLOGICAL PREPARATIONS COMPRISING (1R,2S,5R)-2-ISOPROPYL-5-METHYL-N-(2-(PYRIDIN-2-YL)ETHYL)-CYCLOHEXANE CARBOXAMIDE AND/OR (1R,2S,5R)-N-(4-CYANOMETHYL-PHENYL)-2-ISOPROPYL-5-METHYLCYCLOHEXANE CARBOXAMIDE IN COMBINATION WITH MENTHOXYPROPANEDIOL BEIERSDORF AG. (DE) 2009-12-10 US claimed
US-20080311266-A1 Salt Enhancement GRAY KIMBERLEY H 2008-12-18 US claimed
WO-2008138162-A1 COMPOSITIONS AND THEIR USE GIVAUDAN SA (CH) 2008-11-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11059783-B2 Pyridinyl cyclohexanecarboxamide cooling compounds CBR3, TAS2R31, CTRB2 TRPM8 199/4885ALOX5AP 417/4885HSD11B1 3089/4885
US-20100226864-A1 ALKYL-SUBSTITUTED TETRAHYDROPYRANS AS FLAVORING SUBSTANCES TAS1R3, TAS2R10, TAS2R50 TRPM8 131/4885ALOX5AP 843/4885HSD11B1 3113/4885
US-20090306152-A1 COOLING COSMETIC OR DERMATOLOGICAL PREPARATIONS COMPRISING (1R,2S,5R)-2-ISOPROPYL-5-METHYL-N-(2-(PYRIDIN-2-YL)ETHYL)-CYCLOHEXANE CARBOXAMIDE AND/OR (1R,2S,5R)-N-(4-CYANOMETHYL-PHENYL)-2-ISOPROPYL-5-METHYLCYCLOHEXANE CARBOXAMIDE IN COMBINATION WITH MENTHOXYPROPANEDIOL CUTA, ACMSD, DECR2 TRPM8 41/4885ALOX5AP 574/4885HSD11B1 1070/4885
US-20090311206-A1 COOLING COSMETIC OR DERMATOLOGICAL PREPARATIONS COMPRISING (1R,2S,5R)-2-ISOPROPYL-5-METHYL-N-(2-(PYRIDIN-2-YL)ETHYL)-CYCLOHEXANE CARBOXAMIDE AND/OR (1R,2S,5R)-N-(4-CYANOMETHYL-PHENYL)-2-ISOPROPYL-5-METHYLCYCLOHEXANE CARBOXAMIDE FOR REDUCING SKIN REDDENING CUTA, MC5R, MC1R TRPM8 138/4885ALOX5AP 1446/4885HSD11B1 2515/4885
US-20100035938-A1 Cooling Compounds EBP, HRH1, TAS2R42 TRPM8 742/4885ALOX5AP 1142/4885HSD11B1 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.